New York, New York--(Newsfile Corp. - March 21, 2021) - The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of Astrazeneca Plc (NYSE: AZN) alleging that the Company violated federal securities laws.

Class Period: May 21, 2020 and November 20, 2020
Lead Plaintiff Deadline: March 29, 2021

Learn more about your recoverable losses in AZN:
http://www.kleinstocklaw.com/pslra-1/astrazeneca-plc-loss-submission-form?id=13931&from=5

The filed complaint alleges that Astrazeneca Plc made materially false and/or misleading statements and/or failed to disclose that: (a) initial clinical trials for the Company's COVID-19 vaccine, AZD1222, had suffered from a critical manufacturing error, resulting in a substantial number of trial participants receiving half the designed dosage; (b) clinical trials for AZD1222 consisted of a patchwork of disparate patient subgroups, each with subtly different treatments, undermining the validity and import of the conclusions that could be drawn from the clinical data across these disparate patient populations; (c) certain clinical trial participants for AZD1222 had not received a second dose at the designated time points, but rather received the second dose up to several weeks after the dose had been scheduled to be delivered according to the original trial design; (d) AstraZeneca had failed to include a substantial number of patients over 55 years of age in its clinical trials for AZD1222, despite this patient population being particularly vulnerable to the effects of COVID-19 and thus a high priority target market for the drug; (e) AstraZeneca's clinical trials for AZD1222 had been hamstrung by widespread flaws in design, errors in execution, and a failure to properly coordinate and communicate with regulatory authorities and the general public; (f) as a result of (a)-(e) above, the clinical trials for AZD1222 had not been conducted in accordance with industry best practices and acceptable standards and the data and conclusions that could be derived from the clinical trials was of limited utility; and (g) as a result of (a)-(f) above, AZD1222 was unlikely to be approved for commercial use in the United States in the short term, one of the largest potential markets for the drug.

Shareholders have until March 29, 2021 to petition the court for lead plaintiff status. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.

For additional information about the AZN lawsuit, please contact J. Klein, Esq. by telephone at 212-616-4899 or click the link above.